Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

16.50 -0.31 (-1.84%)
Official Closing Price Updated: 7:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Teva Pharmaceutical Industries ADR

< Previous 1 2 3 4 5 6 7 8 Next >
Teva Reaches Agreement With Florida to Settle the State’s Price Fixing Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reports Fourth Quarter and Full Year 2022 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Financial Guidance at 8 a.m. ET on February 8, 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Nationwide Opioids Settlement to Move Forward After Receiving Broad Support from States
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Teva to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
From Alvotech
Via GlobeNewswire
Teva Finalizes Nationwide Opioid Settlement Terms
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Appointment of Richard Francis as President and CEO
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Unique Collaboration with Rimidi to Expand the Reach of its Respiratory Digital Health Platform
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health Platform
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present Latest Research from the CONNECT1 and CONNECT2 Clinical Trials at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reports Third Quarter 2022 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Clinics Across Florida, New Jersey & California Advancing Mental Health in Underserved Communities – Awarded Funding from Teva Pharmaceuticals, Direct Relief and NAFC
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reaches Agreement With Arkansas to Settle the State’s Price Fixing Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related Outcomes
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reaches Agreement With Georgia to Settle the State’s Price Fixing Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Launches Honestly HD Website to Provide People Living With Huntington’s Disease (HD) Information, Inspiration and Resources on HD Chorea
From Teva Pharmaceutical Industries Limited
Via Business Wire
Studies Show Effectiveness of AJOVY®▼ (fremanezumab) for Treatment of Migraine in Patients With Co-morbid Depression
From Teva Pharmaceutical Industries Limited
Via Business Wire
CONNECT1 Study Published in Journal of Allergy and Clinical Immunology: In Practice Evaluates the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder and Digihaler System to Help Improve Asthma Management
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022
From Teva Pharmaceutical Industries Limited
Via Business Wire
European Commission grants marketing authorization for Ranivisio▼®* (ranibizumab), a biosimilar to Lucentis®**, for age-related macular degeneration (AMD) the most common cause of blindness in developed countries
From Teva Pharmaceutical Industries Limited
Via Business Wire
Is Sanofi A Buy, Despite Recent Stumbles?
Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Volume Surges Spark Turnarounds for These 3 Stocks
There are countless historical chart examples of high volume moves that mark the beginning of sustained rallies or slumps. Let’s tune into a few examples. 
Via MarketBeat
Topics Lawsuit
Exposures Financial Legal
Teva Reports Second Quarter 2022 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reaches Agreement With San Francisco to Settle Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.